[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR052902A1 - Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa - Google Patents

Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa

Info

Publication number
AR052902A1
AR052902A1 ARP060100466A ARP060100466A AR052902A1 AR 052902 A1 AR052902 A1 AR 052902A1 AR P060100466 A ARP060100466 A AR P060100466A AR P060100466 A ARP060100466 A AR P060100466A AR 052902 A1 AR052902 A1 AR 052902A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
hydrogen
cycloalkyl
heterocyclyl
Prior art date
Application number
ARP060100466A
Other languages
English (en)
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AR052902A1 publication Critical patent/AR052902A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden los compuestos de formula (1) y su uso en el tratamiento de trastornos del metabolismo de los lípidos. Reivindicacion 10: Un compuesto caracterizado porque responde a la formula (1), donde x y y son cada uno en forma independiente 1, 2 o 3; W es un enlace directo, -C(O)N(R1)-; -C(O)N[C(O)R1a]-, -N(R1)C(O)N(R1)- -N(R1)C(O)-, -OC(O)N(R1)-, -N(R1)S(O)p- (donde p es 1 o 2), -S(O)pN(R1)- (donde p es 1 o 2), -C(O)-, -OS(O)2N(R1)-, -OC(O)-, -C(O)O-, - N(R1)C(O)O-, -N(R1)C(=NR1a)N(R1)-, -N(R1)C(= S)N(R1)-, -N(R1)C(=NR1a)-, o -C(=NR1a)N(R1)-; V es -C(O)-, -C(O)O-, -C(S)-, -C(O)N(R1)-, -S(O)t- (donde t es 0, 1 o 2), -S(O)pN(R1)- (donde p es 1 o 2), -C(R10)H-, o -C(=NR1a)-; cada R1 se selecciona en forma independiente del grupo formado por hidrogeno; alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por halo, metilo o trifluorometilo; alquilo C2-C6 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por metoxi e hidroxilos; R1a se selecciona del grupo formado por hidrogeno, -OR1, ciano, alquilo C1-6 cicloalquil alquilo; R2 se selecciona del grupo formado por alquilo C1-12, alquenilo C2-12, hidroxialquilo C2-12, hidroxialquenilo C2-12, alcoxi C1-12, alcoxialquilo C2-C12, cicloalquilo C3-C12, cicloalquilC4-C12- alquilo, arilo, aralquilo C7-C12, heterociclilo C3-12, heterociclilC3-C12-alquilo, heteroarilo C1-12, y heteroarilC3-12-alquilo; o R2 es una estructura de anillos multiples que tiene entre 2 y 4 anillos en donde los anillos se seleccionan en forma independiente del grupo formado por cicloalquilo, heterociclilo, arilo y heteroarilo y donde algunos o todos los anillos puede estar fusionados entre sí; R3 se selecciona del grupo formado por alquilo C1-12, alquenilo C2-12, hidroxialquilo C2-12, hidroxialquenilo C2-12, alcoxi C1-12, alcoxialquilo C2-C12, cicloalquilo C3-C12, cicloalquilC4-C12-alquilo, arilo, aralquilo C7- C12, heterociclilo C3-12, heterociclilC3-C12-alquilo, heteroarilo C1-12, y heteroarilC3-12-alquilo; o R3 es una estructura de anillos multiples que tiene entre 2 y 4 anillos en donde los anillos se seleccionan en forma independiente del grupo formado por cicloalquilo, heterociclilo, arilo y heteroarilo y donde algunos o todos los anillos puede estar fusionados entre sí; R4 y R5 se seleccionan cada uno en forma independiente entre hidrogeno, fluoro, cloro, metilo, metoxi, trifluorometilo, ciano, nitro, o -N(R12)2; R6, R6a, R7, R7a, R8, R8a, R9, y R9a se seleccionan cada uno en forma independiente entre hidrogeno o alquilo C1-3; o R6 y R6a juntos, o R7 y R7a juntos, o R8 y R8a juntos, o R9 y R9a juntos son un grupo oxo, con la salvedad de que cuando V es -C(O)-, R7 y R7a juntos o R8 y R8a juntos no forman un grupo oxo, mientras que los restantes R6, R6a, R7, R7a, R8, R8a, R9, y R9a se seleccionan cada uno en forma independiente entre hidrogeno o alquilo C1-3; o uno de R6, R6a, R7, y R7a junto con uno de R8, R8a, R9 y R9a forman un puente alquileno, mientras que los restantes R6, R6a, R7, R7a, R8, R8a, R9, y R9a se seleccionan cada uno en forma independiente entre hidrogeno o alquilo C1-3; R10 es hidrogeno o alquilo C1-3; y cada R12 se selecciona en forma independiente entre hidrogeno, o alquilo C1-6; un estereoisomero, enantiomero, o tautomero del mismo, una sal aceptable para uso farmacéutico del mismo, una composicion farmacéutica del mismo o una prodroga del mismo.
ARP060100466A 2005-02-09 2006-02-09 Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa AR052902A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/055,034 US7754711B2 (en) 2003-07-30 2005-02-09 Pyridazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
AR052902A1 true AR052902A1 (es) 2007-04-11

Family

ID=36646207

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100466A AR052902A1 (es) 2005-02-09 2006-02-09 Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa

Country Status (16)

Country Link
US (1) US7754711B2 (es)
EP (1) EP1851205B1 (es)
JP (1) JP5114212B2 (es)
CN (2) CN101160289A (es)
AR (1) AR052902A1 (es)
AT (1) ATE553096T1 (es)
AU (2) AU2006212763A1 (es)
BR (1) BRPI0606817A2 (es)
CA (1) CA2597069C (es)
ES (1) ES2385577T3 (es)
GT (1) GT200600045A (es)
MX (1) MX2007009593A (es)
MY (1) MY141939A (es)
PE (2) PE20100561A1 (es)
TW (1) TWI320316B (es)
WO (1) WO2006086447A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7759348B2 (en) * 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7592343B2 (en) * 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003332A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
WO2006034341A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799668A1 (en) * 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
BRPI0515505A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
BRPI0515488A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
EP1804792A1 (en) * 2004-09-20 2007-07-11 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
EP2086970B1 (en) 2006-08-24 2014-02-26 Novartis AG 2-(pyrazin-2-yl)-thiazole and 2-(1h pyrazol-3-yl)-thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
WO2008029266A1 (en) * 2006-09-08 2008-03-13 Glenmark Pharmaceuticals S.A. Stearoyl coa desaturase inhibitors
CA2664849A1 (en) * 2006-10-20 2008-04-24 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
US8383643B2 (en) 2009-07-28 2013-02-26 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
WO2011030312A1 (en) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
CA2873817A1 (en) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
CA2998493A1 (en) 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3566055A4 (en) 2017-01-06 2020-12-02 Yumanity Therapeutics, Inc. TREATMENT METHODS FOR NEUROLOGICAL DISORDERS
KR102588982B1 (ko) 2017-03-15 2023-10-12 오가노보, 인크. 파네소이드 x 수용체 효능제 및 이의 용도
DK3596053T3 (da) 2017-03-15 2023-09-25 Organovo Inc Farnesoid-x-receptoragonister og anvendelser deraf
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2020061113A1 (en) 2018-09-18 2020-03-26 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US20230078764A1 (en) * 2019-03-22 2023-03-16 Yumanity Therapeutics, Inc. Compounds and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
KR100443893B1 (ko) * 1996-01-15 2004-10-15 얀센 파마슈티카 엔.브이. 혈관형성억제제피리다진아민
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
DE60142692D1 (de) 2000-02-24 2010-09-09 Xenon Genetics Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
ATE374765T1 (de) 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
AU2001289457A1 (en) 2000-09-26 2002-04-08 Xenon Genetics Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
BR0210030A (pt) 2001-06-15 2004-08-10 Yamanouchi Pharma Co Ltd Derivado de fenilpiridinacarbonilpiperazina
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
CA2476186C (en) 2002-03-13 2011-07-19 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
BR0308081A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Inibidores de histona desacetilase
KR101255356B1 (ko) * 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040024658A1 (en) 2002-08-05 2004-02-05 General Electric Company System and method for providing asset management and tracking capabilities
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
DK1648874T3 (da) 2003-07-30 2012-01-23 Xenon Pharmaceuticals Inc Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer
CN100558713C (zh) * 2003-07-30 2009-11-11 泽农医药公司 哒嗪衍生物及其作为治疗剂的用途
RU2006105716A (ru) * 2003-07-30 2007-09-10 Зинон Фармасьютиклз Инк. (Ca) Производные пиридазина и их применение в качестве терапевтических средств
BRPI0515505A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
WO2007009236A1 (en) * 2005-07-20 2007-01-25 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Also Published As

Publication number Publication date
MX2007009593A (es) 2007-10-16
CA2597069C (en) 2011-09-20
EP1851205B1 (en) 2012-04-11
ATE553096T1 (de) 2012-04-15
PE20061065A1 (es) 2006-12-01
CA2597069A1 (en) 2006-08-17
US7754711B2 (en) 2010-07-13
AU2006212763A1 (en) 2006-08-17
CN102600162A (zh) 2012-07-25
US20060009459A1 (en) 2006-01-12
MY141939A (en) 2010-07-30
JP5114212B2 (ja) 2013-01-09
BRPI0606817A2 (pt) 2009-07-14
WO2006086447A2 (en) 2006-08-17
WO2006086447A3 (en) 2007-04-05
AU2010227003B2 (en) 2012-06-14
AU2010227003A1 (en) 2010-10-28
CN101160289A (zh) 2008-04-09
TW200638935A (en) 2006-11-16
EP1851205A2 (en) 2007-11-07
ES2385577T3 (es) 2012-07-26
PE20100561A1 (es) 2010-08-25
GT200600045A (es) 2006-09-13
TWI320316B (en) 2010-02-11
JP2008530098A (ja) 2008-08-07

Similar Documents

Publication Publication Date Title
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
AR051093A1 (es) Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
AR047557A1 (es) Compuestos derivados de piridazina y su uso como agentes terapeuticos
AR056103A1 (es) Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR061867A1 (es) Derivados de (4,5') bipirimidil 6,4' - diamina como inhibidores de proteinquinasa
AR070852A1 (es) Derivados de piridazina y su uso como agentes terapeuticos
AR051026A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
DOP2006000076A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR064831A1 (es) Derivados de espiropiperidina-glicinamida
AR078756A1 (es) Moduladores alostericos positivos (map)

Legal Events

Date Code Title Description
FB Suspension of granting procedure